D Hageman1, H J P Fokkenrood2, P P M Essers3, M J W Koelemay4, J C Breek5, A C Vahl6, M R M Scheltinga7, J A W Teijink8. 1. Department of Vascular Surgery, Catharina Hospital, Eindhoven, The Netherlands; Department of Epidemiology, CAPHRI School for Public Health and Primary Care, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. 2. Department of Vascular Surgery, Rijnstate, Arnhem, The Netherlands. 3. Centre of Expertise Care Control, CZ, Tilburg, The Netherlands. 4. Department of Vascular Surgery, Academic Medical Centre, Amsterdam, The Netherlands. 5. Department of Vascular Surgery, Martini Hospital, Groningen, The Netherlands. 6. Department of Vascular Surgery, OLVG, Amsterdam, The Netherlands. 7. Department of Vascular Surgery, Máxima Medical Centre, Veldhoven, The Netherlands. 8. Department of Vascular Surgery, Catharina Hospital, Eindhoven, The Netherlands; Department of Epidemiology, CAPHRI School for Public Health and Primary Care, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. Electronic address: joep.teijink@catharinaziekenhuis.nl.
Abstract
OBJECTIVE/ BACKGROUND: A previous budget impact analysis regarding a supervised exercise therapy (SET) first treatment strategy (stepped care model [SCM]) for Dutch patients with intermittent claudication (IC) showed a low referral rate in 2009, despite solid evidence of the effectiveness of SET programs. Recently, several campaigns have stimulated stakeholders in the field to adopt a SET first strategy in patients with IC. The aim of the present study was to reassess SCM adherence after a 2 year period. METHODS: IC related invoices of patients in 2011 were obtained from a large Dutch health insurance company (3.5 million persons). Patients were divided into two groups based on their initial treatment. A SET group had started SET between 12 months before (initiated by general practitioner) and 3 months after (initiated by vascular surgeon) presentation at a vascular surgery outpatient clinic. An intervention (INT) group was treated by revascularisation within 3 months of outpatient presentation. Costs of IC treatment in this 2011 cohort were compared with the earlier 2009 cohort. RESULTS: IC related invoices of 4135 patients were available. In 2011, the initial treatment was SET in 56% (2009: 34%; +22% [p < .001]) and INT in 44% (2009: 66%; -22% [p < .001]) of the IC population. Additional revascularisation was performed in 19% of patients in the SET group (2009: 6%; +13% [p < .001]) and also in 19% of patients in the INT group (2009: 35%; -16% [p < .001]). Later on, 29% of patients in the INT group were referred for SET (2009: 10%; +19% [p < .001]). Average costs of IC treatment per patient in 2011 were 6% lower than in 2009 (€6885 vs. €7300; p = .020). CONCLUSION: A 22% increase in adherence to SET as a first treatment strategy in Dutch patients with IC was attained between 2009 and 2011. This shift suggests successful SCM implementation resulting in lower costs for the national healthcare system.
OBJECTIVE/ BACKGROUND: A previous budget impact analysis regarding a supervised exercise therapy (SET) first treatment strategy (stepped care model [SCM]) for Dutch patients with intermittent claudication (IC) showed a low referral rate in 2009, despite solid evidence of the effectiveness of SET programs. Recently, several campaigns have stimulated stakeholders in the field to adopt a SET first strategy in patients with IC. The aim of the present study was to reassess SCM adherence after a 2 year period. METHODS: IC related invoices of patients in 2011 were obtained from a large Dutch health insurance company (3.5 million persons). Patients were divided into two groups based on their initial treatment. A SET group had started SET between 12 months before (initiated by general practitioner) and 3 months after (initiated by vascular surgeon) presentation at a vascular surgery outpatient clinic. An intervention (INT) group was treated by revascularisation within 3 months of outpatient presentation. Costs of IC treatment in this 2011 cohort were compared with the earlier 2009 cohort. RESULTS: IC related invoices of 4135 patients were available. In 2011, the initial treatment was SET in 56% (2009: 34%; +22% [p < .001]) and INT in 44% (2009: 66%; -22% [p < .001]) of the IC population. Additional revascularisation was performed in 19% of patients in the SET group (2009: 6%; +13% [p < .001]) and also in 19% of patients in the INT group (2009: 35%; -16% [p < .001]). Later on, 29% of patients in the INT group were referred for SET (2009: 10%; +19% [p < .001]). Average costs of IC treatment per patient in 2011 were 6% lower than in 2009 (€6885 vs. €7300; p = .020). CONCLUSION: A 22% increase in adherence to SET as a first treatment strategy in Dutch patients with IC was attained between 2009 and 2011. This shift suggests successful SCM implementation resulting in lower costs for the national healthcare system.
Authors: Marijn Ml van den Houten; Sandra Cp Jansen; Anneroos Sinnige; Lijckle van der Laan; Patrick Whe Vriens; Edith M Willigendael; Jan-Willem Hp Lardenoije; Jan-Willem M Elshof; Eline S van Hattum; Maarten A Lijkwan; Ivan Nyklíček; Ellen V Rouwet; Mark Jw Koelemay; Marc Rm Scheltinga; Joep Aw Teijink Journal: BMJ Open Date: 2019-02-19 Impact factor: 2.692
Authors: Amy E Harwood; Sean Pymer; Lee Ingle; Patrick Doherty; Ian C Chetter; Belinda Parmenter; Christopher D Askew; Gary A Tew Journal: BMJ Open Sport Exerc Med Date: 2020-11-05
Authors: Anneroos Sinnige; Steffie Spruijt; Mickey Saes; Philip J Van der Wees; Thomas J Hoogeboom; Joep A W Teijink Journal: Phys Ther Date: 2022-01-01